In Brief: Chartex
This article was originally published in The Tan Sheet
Executive Summary
Chartex: Claims to have rights to the clinical data referenced by Wisconsin Pharmacal's May 1993 premarket approval application for the Reality female condom. In a Nov. 13 letter to FDA, Chartex responded to Wisconsin Pharmacal's August request to the agency to withdraw Chartex' premarket approval application for its own female condom ("The Tan Sheet" Aug. 28, p. 18). Wisconsin Pharmacal argued in its petition that it has sole rights to the Family Health International data. The Chartex letter maintained that Wisconsin Pharmacal's 1993 application authorized the company to cross-reference the data...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: